Moreover, emerging evidence has suggested that pharmacological inhibition of TMEM16A might be beneficial for the treatment of TMEM16A-associated diseases such as asthma (Huang et al., 2012), vasoconstriction of cerebral arteries (Wang et al., 2016), and diarrhea (Ko et al., 2014). This evidence concerns the gene ANO1 and asthma.